Dr Lonial discusses a study on ixazomib as post-induction maintenance therapy for transplant-ineligible, newly-diagnosed MM.
BTK inhibitor therapy is an effective option for patients with CLL resistant to venetoclax, according to data presented at the virtual 2020 EHA Annual Congress.
Courtney DiNardo, MD, discusses the results from the VIALE-A study, which evaluated azacitidine with or without venetoclax in older patients with newly diagnosed AML.
Abdulraheem Yacoub, MD, discusses the results from a phase 2 study, which evaluated optimal dosing and efficacy of the addition of parsaclisib in patients with myelofibrosis with suboptimal response…
Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.
Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.
Asciminib is well-tolerated and shows promising clinical activity in patients with Ph+ CML with baseline BCR-ABL1 levels less than 1%.
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.
Stay in the know.
OncNet Newsletter